Regulus Therapeutics Competitors and Similar CompaniesClear all
Regulus Therapeutics's competitors and similar companies include Alnylam.
 Regulus Therapeutics Regulus Therapeutics is a biopharmaceutical company involved in the R&D of high-impact medicines based on microRNAs. |  Alnylam Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments. | |
Founding Date | Founding Date 2007 | Founding Date 2002 |
Type | Type Public | Type Public |
Tags | ||
Locations | Locations San Diego, US HQ | |
Employees | Employees 2462% decrease | Employees 1,32324% increase |
Valuation ($) | Valuation ($) 105.4 m | Valuation ($) 36.5 b |
Financial | ||
Net income | Net income ($46.4m) (FY, 2024) | Net income $313.7m (FY, 2025) |
Funding | ||
Total funding raised | Total funding raised $ 10m | Total funding raised $ 1.5b |
For sources of this data, please see the company profile
View Company Profiles
Alnylam
HQ
Cambridge, US
Employees
1,323↑ 24% increase
Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments.
View company